Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisInterferon beta for secondary progressive multiple sclerosisInterferon Beta for Primary Progressive Multiple SclerosisInterferon Beta for Primary Progressive Multiple SclerosisRelating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisProgressive multiple sclerosisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisCost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Progressive multiple sclerosis: from pathogenic mechanisms to treatment.Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis ProgressionA multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigueTargeting progressive neuroaxonal injury: lessons from multiple sclerosis.Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational studyThe safety and efficacy of IFN-beta products for the treatment of multiple sclerosis.Relapses and disability accumulation in progressive multiple sclerosisClinical trials in progressive multiple sclerosis: lessons learned and future perspectivesDevelopment of interferon-beta as a therapy for multiple sclerosis.Interferon-beta1a treatment for multiple sclerosis.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisInterferon beta and glatiramer acetate therapy.Interferon-beta treatment for multiple sclerosis.MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs.Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.Disease-modifying treatments for progressive multiple sclerosis.Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?Simultaneous Confidence Intervals Based on the Percentile Bootstrap Approach.A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].Progressive MS trials: Lessons learned.Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.Quality of life among young patients with ischaemic stroke compared with patients with multiple sclerosis.Health-related quality of life in secondary progressive multiple sclerosis.Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.
P2860
Q22241795-A92769B6-E517-463A-BE05-D6858D0A458BQ24202108-AD0B3D9F-A3F4-489C-A094-647314CCFF2FQ24203879-354CDBEF-E62E-4AA2-9F7B-C1EFEC7072A5Q24240620-1F0C483A-C496-449C-AC54-3B08C14B4CF9Q24241541-16F4243C-4AB2-4CB8-BB37-7DFA08BC2FA3Q26828463-EE64849E-0D70-446A-A087-C86CE52ACDFDQ26861772-EA3A3831-B1FE-4278-A536-6B642B0E6551Q27000269-C57B08FF-3EB6-41CD-AD20-F0A7C322CC77Q30651607-DCD23DCF-42E0-4CAB-96E5-452627963C8EQ31139925-4D071A5E-34C4-450E-BC0C-DFCE17F4C5ACQ33392874-0EFAA6F6-4268-4DEC-9BDF-B70447E46A0BQ33571970-CB8AEB1A-B38A-4BF3-AC70-ADC3D869B7CAQ34003724-6DCAA4FC-3C90-4C3D-8F3E-D0B3D4CCF2B6Q34389325-B7AA7412-50A8-46FB-B9EC-DCDFF188CE56Q34579232-8F8D4D2D-A099-4956-B183-C854B0346DEDQ35106567-52843DAB-A059-4C1A-B798-661FE82739F1Q35182733-EC14EB3E-8808-4DCA-A2A7-B0A2E06C51A5Q35967412-7C9FC641-B1D9-4237-8BFE-0A1D99BD3BF7Q36106748-5B418048-4291-4D65-B731-CBCDF77AFE68Q36353053-9AA65C53-1FC0-479B-AF71-3AB91A83330AQ36484443-38D16909-863A-426B-9FD0-9990F8C32433Q36568660-640B03E5-0361-49DA-9F0F-10C2BBE40BB3Q36963178-9326C8BD-19BD-4014-AF6E-BF1E1C9CAE3AQ37398272-5139F3B0-C628-443D-8933-36194119C12CQ37611215-060D2B12-9B98-46FB-AC42-990D7C9EC41CQ37773270-475678FC-8949-42CF-8368-A7D3357CA54DQ38142030-C8333B10-2804-4D94-AEA4-D3E4EFBE278FQ38677868-DA5B9F7E-67BB-4F4B-87F0-B219AD4EF3BCQ39278699-7ECE6EF7-3D70-4706-9281-B301F5B77762Q39603838-666F39BE-E4FB-435F-BA88-DC64134A10FCQ41369774-D6A449F9-7D19-42D2-A0B2-EA412D58AE1BQ41857200-69D14243-CA6F-4567-AFFE-4B3ECB794FA3Q45155454-AD3954D0-081E-4630-A6FB-88B36A5DC314Q47892257-FAD86E0F-BEBB-4B2F-8EC1-1665254C4C3FQ48128432-F58C1BE3-A576-4443-A40D-9B86636A327DQ48457354-38BBBDAA-AF65-4045-BBE7-F2BDF9983415Q48471623-B094DE07-D4EC-4F12-8A92-1E659B1FBDA0Q48607199-61903CB6-B48D-4E12-AB6F-3A5A84FCB06CQ48785648-CBFA93CE-96D4-4BC2-B6B8-161A3E95C024Q51931814-70CBE54D-FDD4-4BD1-9EE3-5A588B6E73AF
P2860
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@ast
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@en
type
label
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@ast
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@en
prefLabel
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@ast
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@en
P2093
P2860
P921
P356
P1476
Multicentre, randomised, doubl ...... rogressive multiple sclerosis.
@en
P2093
Andersen O
Elovaara I
Färkkilä M
Mellgren SI
Sandberg-Wollheim M
Soelberg Sørensen P
P2860
P304
P356
10.1136/JNNP.2003.010090
P407
P577
2004-05-01T00:00:00Z